Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms

NCT01164163 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01164163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01164163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2010
Completion date
Not reported
Enrollment
49 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloproliferative disorders, leukemia, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, unspecified childhood solid tumor, protocol specific